Filing Flows

Filing Flows › Companies › Taysha Gene Therapies › Cash flow

Taysha Gene Therapies cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$40.4M in Q2 2026 · −$133M over twelve months

Operating cash flow−$40.4M
Capital spending$1K
Free cash flow−$40.4M

Analysis

In Q2 2026, Taysha Gene Therapies generated −$40.4M of operating cash flow and spent −$1K on capital projects, leaving free cash flow of −$40.4M. That is $20.2M less than in Q2 2025 (−$20.2M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$132M; the largest uses were operating cash flow ($132M), other investing ($2.9M), capital spending ($381K); besides operations, cash came from other financing ($275M), shares issued ($260K); the cash balance rose by $140M.

Operating cash flow was −$40.4M against net income of −$46.6M. The largest differences: stock-based pay +$5.8M, payables +$4.6M, gains on disposals +$4.0M.

Free cash flow

Taysha Gene Therapies: free cash flow by quarterTaysha Gene Therapies: free cash flow by quarter−$21.6MQ3 2024−$18.3MQ4 2024−$22.4MQ1 2025−$20.2MQ2 2025−$24.3MQ3 2025−$27.0MQ4 2025−$40.9MQ1 2026−$40.4MQ2 2026
Operating cash flow less capital spending.
Taysha Gene Therapies: operating cash flow against capital spendingTaysha Gene Therapies: operating cash flow against capital spendingOperating cash flowCapital spending−$21.6M$35KQ3 2024−$18.3M−$2KQ4 2024−$22.0M$378KQ1 2025−$20.2M$2KQ2 2025−$24.2M$108KQ3 2025−$26.7M$250KQ4 2025−$40.9M$24KQ1 2026−$40.4M−$1KQ2 2026
Latest (Q2 2026): Operating cash flow −$40.4M, Capital spending −$1K.

Capital allocation, year by year

Taysha Gene Therapies: where the cash came from (up) and went (down), by fiscal yearTaysha Gene Therapies: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$117MFY2021: Capital spending −$15.3MFY2021FY2022: Operating cash flow −$88.4MFY2022: Shares issued $253KFY2022: Capital spending −$20.6M$253KFY2022FY2023: Operating cash flow −$73.0MFY2023: Shares issued $568KFY2023: Capital spending −$3.9M$568KFY2023FY2024: Operating cash flow −$81.2MFY2024: Shares issued $89KFY2024: Capital spending −$374K$89KFY2024FY2025: Operating cash flow −$93.1MFY2025: Shares issued $1.2MFY2025: Capital spending −$738K$1.2MFY2025
Over these 5 years operating cash flow totalled −$453M; the largest uses were operating cash flow ($453M) and capital spending ($40.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$455M
Debt$49.3M
Net cash$406M
Cash runway3.4 years

Taysha Gene Therapies is burning cash: its operations consume cash, a free cash flow of −$133M a year at the current rate against $455M of cash and investments: a runway of about 3.4 years before any new financing.

Where the cash came from and went

Taysha Gene Therapies: sources (+) and uses (−) of cash, Q2 2026Taysha Gene Therapies: sources (+) and uses (−) of cash, Q2 2026Other financing$216MCash drawn (+) / kept (−)−$176MOperating cash flow−$40.4MShares issued$441KCapital spending$1K
Taysha Gene Therapies: sources (+) and uses (−) of cash, TTM to Q2 2026Taysha Gene Therapies: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$275MCash drawn (+) / kept (−)−$140MOperating cash flow−$132MOther investing−$2.9MCapital spending−$381KShares issued$260K

From profit to cash

Taysha Gene Therapies: net income to operating cash flow, Q2 2026Taysha Gene Therapies: net income to operating cash flow, Q2 2026Net income−$46.6MDepreciation & amortization$400KStock-based pay$5.8MGains on disposals$4.0MOther non-cash$96KPayables$4.6MPrepaid and other assets−$645KOperating cash flow−$40.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$40.4M$1K$441K−$176M−$40.4M
Q1 2026−$40.9M−$24K$516K$43.2M−$40.9M
Q4 2025−$26.7M−$250K$1.0M−$22.6M−$27.0M
Q3 2025−$24.2M−$108K$84K$15.4M−$24.3M
Q2 2025−$20.2M−$2K—−$196M−$20.2M
Q1 2025−$22.0M−$378K$75K$22.4M−$22.4M
Q4 2024−$18.3M$2K—$18.7M−$18.3M
Q3 2024−$21.6M−$35K$63K$15.1M−$21.6M

Taysha Gene Therapies: income statement and cash flow

Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%. The chart follows the revenue to costs, profit and cash.

Taysha Gene Therapies: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.